Stopping long-acting inhalers for chronic obstructive pulmonary disease (COPD) can lead to a sharp rise in flare-ups for ...

GSK plc GSK announced that the European Commission has approved its blockbuster respiratory drug, Nucala (mepolizumab), for ...

GSK’s Nucala receives European Commission approval to treat chronic obstructive pulmonary disease: London, UK Saturday, February 7, 2026, 09:00 Hrs [IST] GSK plc announced the E ...

Researchers at the UNC School of Medicine have developed a tool that can identify airway mucus abnormalities in patients with ...

When appropriate, surgery remains the most effective treatment option for non-small cell lung cancer (NSCLC), including for patients with COPD, said Friedberg, professor in the Department of Thoracic ...

While chronic obstructive pulmonary disease can make exercise more challenging, regular physical activity may actually improve your symptoms and make it easier to perform everyday tasks. In addition ...

GSK (GSK) on Friday announced that the European Commission has approved its Nucala asthma therapy for patients with chronic ...

Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disorder characterised by persistent airflow limitation and chronic inflammation. It is a leading cause of morbidity and ...

November is National Chronic Obstructive Pulmonary Disease Awareness Month. It’s time to raise awareness about lung disease within our communities. By understanding the causes, reducing our risk ...

The primary finding from the clinical trials for the COPD biologics is reduced annual exacerbations by 30% (BOREAS trial) and 34% (NOTUS trial). In the BOREAS trial, in addition to reduced ...

Chronic obstructive pulmonary disease (COPD) remains a substantial contributor to morbidity and mortality in the United States with an estimated 3.8% age-adjusted prevalence and 141,733 COPD deaths ...